Timothy P. Coughlin's most recent trade in Travere Therapeutics Inc was a trade of 10,000 Common Stock done at an average price of $26.5 . Disclosure was reported to the exchange on June 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.52 per share. | 12 Jun 2026 | 10,000 | 66,250 (0%) | 0% | 26.5 | 265,200 | Common Stock |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Sale of securities on an exchange or to another person at price $ 50.07 per share. | 12 Jun 2026 | 10,000 | 56,250 (0%) | 0% | 50.1 | 500,747 | Common Stock |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Vir biotech Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2026 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Vir biotech Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2026 | 16,000 | 16,000 | - | - | Stock Option (Right to Buy) | |
| Vir biotech Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2026 | 8,000 | 16,000 (0%) | 0% | 0 | Common Stock | |
| Vir biotech Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2026 | 8,000 | 8,000 (0%) | 0% | 0 | Common Stock | |
| Adc Therapeutics SA | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2026 | 45,000 | 85,000 | - | 0 | Common Shares | |
| Adc Therapeutics SA | Timothy P. Coughlin | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.08 per share. | 01 Jun 2026 | 12,600 | 72,400 | - | 3.1 | 38,808 | Common Shares |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2026 | 12,000 | 12,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2026 | 4,000 | 56,250 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Sale of securities on an exchange or to another person at price $ 43.49 per share. | 15 May 2026 | 3,250 | 52,250 (0%) | 0% | 43.5 | 141,343 | Common Stock |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2026 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Sale of securities on an exchange or to another person at price $ 35.03 per share. | 31 Oct 2025 | 18,000 | 55,500 (0%) | 0% | 35.0 | 630,601 | Common Stock |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.44 per share. | 31 Oct 2025 | 10,000 | 73,500 (0%) | 0% | 17.4 | 174,400 | Common Stock |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 10,000 | 0 | - | - | Director stock option (right to buy) | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.33 per share. | 31 Oct 2025 | 8,000 | 63,500 (0%) | 0% | 16.3 | 130,640 | Common Stock |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 8,000 | 0 | - | - | Director stock option (right to buy) | |
| Adc Therapeutics SA | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 80,000 | 80,000 | - | - | Stock Options (Right to Buy) | |
| Adc Therapeutics SA | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 40,000 | 40,000 | - | 0 | Common Shares | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 6,500 | 55,500 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Timothy Coughlin P. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Timothy P. Coughlin | Director | 07 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 30 May 2024 | 50,000 | 56,000 (0%) | 0% | 1.8 | 87,500 | Common Stock |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 6,500 | 49,000 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Timothy P. Coughlin | Director | 06 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 17 May 2023 | 6,000 | 6,000 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 17 May 2023 | 6,000 | 0 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 6,000 | 6,000 (0%) | 0% | - | Common stock | |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 6,000 | 0 | - | - | Restricted Stock Unit | |
| Fate Therapeutics Inc | Timothy P. Coughlin | Director | 09 Jun 2022 | 11,893 | 11,893 | - | - | Stock Option (Right to Buy) | ||
| Fate Therapeutics Inc | Timothy P. Coughlin | Director | 09 Jun 2022 | 8,650 | 9,892 (0%) | 0% | 0 | Common Stock | ||
| Fate Therapeutics Inc | Timothy P. Coughlin | Director | 03 Jun 2022 | 1,439 | 57,632 (0%) | 0% | 22.8 | 32,824 | Common Stock | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 3,000 | 38,000 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 6,000 | 6,000 | - | - | Restricted Stock Units |